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Abstract
Women with a history of hypertensive disorders of pregnancy (HDP; preeclampsia and gestational hypertension) or
delivering low birth weight offspring (LBW;\ 2500 g) have twice the risk of cardiovascular disease (CVD). We aimed to
study the extent to which history of these pregnancy complications improves CVD risk prediction above and beyond
conventional predictors. Parous women attended standardized clinical visits in Sweden. Data were linked to registries of
deliveries and CVD. Participants were followed for a first CVD event within 10 years from age 50 (n = 7552) and/or
60 years (n = 5360) and the predictive value of each pregnancy complication above and beyond conventional predictors
was investigated. History of LBW offspring was associated with increased risk of CVD when added to conventional
predictors in women 50 years of age [Hazard ratio 1.68, 95% Confidence interval (CI) 1.19, 2.37] but not at age 60 (age
interaction p = 0.04). However, at age 50 years CVD prediction was not further improved by information on LBW
offspring, except that a greater proportion of the women who developed CVD were assigned to a higher risk category
(categorical net reclassification improvement for events 0.038, 95% CI 0.003, 0.074). History of HDP was not associated
with CVD when adjusted for reference model predictors. In conclusion, a history of pregnancy complications can identify
women with increased risk of CVD midlife. However, considered with conventional risk factors, history of HDP or having
delivered LBW offspring did not meaningfully improve 10-year CVD risk prediction in women age 50 years or older.
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Introduction
Women with a history of hypertensive disorders of preg-
nancy (HDP; preeclampsia and gestational hypertension) or
delivering low birth weight (LBW) offspring have twice
the risk of cardiovascular disease (CVD) later in life [1–5].
Current CVD prevention guidelines in the United States [6]
and Europe [7] recommend that a woman’s reproductive
history should be part of her CVD risk assessment. Com-
plications during pregnancy are associated with earlier
development of conventional CVD risk factors [8],
increased risk of chronic kidney disease [9] and diabetes
mellitus [10], but the strength of the relative risk of preg-
nancy complications for CVD appears to decline with age
[11, 12]. However, it is unknown whether information on
prior HDP or LBW offspring improves CVD risk predic-
tion above and beyond current risk prediction models based
on conventional CVD risk factors [7, 13, 14].
We investigated the extent to which information on
history of HDP or ever delivering LBW offspring added
value to the 10-year prediction of CVD in parous middle-
aged women. To accomplish this, we predicted the risk of
CVD utilizing a conventional prediction model [15] in a
population-based cohort with CVD risk factors measured at
baseline, and separately evaluated its performance fol-
lowing the inclusion of HDP or LBW offspring history.
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Methods
We used data from a prospectively assessed cohort with
standardized clinical assessments in primary care (the
Va¨sterbotten Intervention Program) [16, 17] in combina-
tion with population-based registries on pregnancy history,
in-patient care, and cause of death. Data on emigration
were collected from Statistics Sweden (the government
agency responsible for the management of Swedish popu-
lation data). Data were matched via the personal identifi-
cation number, which is unique for all individuals residing
in Sweden [18]. All registry data were collected in accor-
dance with Swedish law and the study was approved by the
Ethical Review Board at Lund University, Sweden (2014/
337).
Clinical assessment in primary care
All residents in Va¨sterbotten County (population 264,000,
as of June 2016) in Northern Sweden have been, since the
early 1990s, invited to visit their primary care provider at
ages 50 and 60 years [17]. The goal of these visits is pre-
ventive health care with focus on cardiometabolic risk
factors. Approximately 50–70% of the eligible population
attends. Visits are standardized and generally follow an
overnight fast. Further description of clinical visits can be
found in the Supplement.
Pregnancy complication data
For deliveries from 1955 to 1972, we utilized a local birth
register covering the county of Va¨sterbotten and the adja-
cent county Va¨sternorrland. Offspring birth weight was
available for all as a binary variable (\ 2500 or C 2500 g).
For deliveries from 1973 onward, we used the Swedish
Medical Birth Register (MBR). Diagnoses during preg-
nancy were classified according to the International Clas-
sification of Disease (ICD): ICD-8 was used until 1986,
ICD-9 from 1987 to 1996, and ICD-10 was introduced in
1997. We defined HDP (i.e. preeclampsia/eclampsia/tox-
emia or gestational hypertension) according to corre-
sponding ICD codes (Supplement). The MBR has been
extensively used for research, including investigations on
the association between HDP and fetal growth restriction,
and maternal CVD [19, 20]. The local birth register and the
MBR are further described in the Supplement.
Cardiovascular disease events
All hospitalizations in Sweden since 1987 are reported to
the Swedish National In-Patient Register and diagnoses are
registered as ICD codes (ICD-9: 1987–1996, ICD-10:
1996–2014) [21]. Similarly, the Swedish Cause of Death
Register captures mortality related diagnoses. For the
purpose of this study, we defined incident events (ICD
codes given in Supplement) as myocardial infarction,
angina, stroke and transient ischemic attack (TIA). When
utilizing diagnoses related to deaths, we included the first
diagnosis registered and underlying causes of death.
Study sample
Our study sample comprised women born 1936–1952 who
visited their primary care provider for a standardized
clinical assessment between January 1, 1991 and December
31, 2004, at approximately age 50 or 60 years (Fig. 1). In
order to capture full reproductive history, we restricted
analyses to those born 1936 and later (i.e. 19 years or
younger at the start of pregnancy registration in 1955) and
excluded women who did not reside in the geographical
area of the local birth registry in young adulthood. Only
women with at least one confirmed delivery were included
in the analysis. In total, 11,110 parous women (77.8% of
those eligible without prior CVD at the clinical assessment)
were included in our final study sample. In analyses not
stratified by age, these 11,110 women contributed data only
from their last clinical assessment that included 10-years of
post-assessment follow-up. However, in the analyses
stratified by age at clinical assessment, women who had
more than one clinical assessment could contribute with
Fig. 1 Study sample identification. Flowchart of women included in
the study sample. CVD: Cardiovascular disease
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data at both ages, resulting in a total of 7552 women
observed from age 50 and 5360 women from age 60 years.
Reference prediction model
We sought to investigate the incremental value of a history
of HDP or delivering LBW offspring in CVD risk predic-
tion, building upon established risk factors included in a
published prediction model. We chose as the reference
model the ‘‘lab-based model’’ published by Gaziano et al.
(c-index 0.83), and accordingly replicated that model’s
choice, and parameterization, of the conventional risk
factors [15]. This model utilized CVD risk factors mea-
sured at baseline in our sample [age, log total-cholesterol,
log systolic blood pressure, anti-hypertensive medication
(yes/no), diabetes mellitus (yes/no), and smoking (yes/no)]
and a composite CVD endpoint, including both hard CVD
events and diagnoses indicating severe CVD, similar to that
defined in this study.
Statistical analyses
Participants were followed from the clinical assessment
until the date of a CVD event, death, emigration, or
10 years from the baseline visit, whichever came first. We
used Cox proportional hazards regression models for all
prediction analyses. To assess the proportional hazards
assumption we used Schoenfeld residual plots and cumu-
lative Martingale residuals. We first studied the association
between each pregnancy complication and 10-year CVD in
univariate models and then adjusted for all variables
included in the reference prediction model. If indepen-
dently associated with CVD in the latter model, we pro-
ceeded to specifically evaluate the predictive value of the
pregnancy complication when added to the reference
model. As we hypothesized a priori that the pregnancy
variables would add more to CVD prediction at younger
ages, i.e. at a time point with lower burden of traditional
cardiovascular risk factors, we tested multiplicative inter-
actions between age at baseline and each pregnancy
complication.
To evaluate model performance, we first estimated the
beta coefficients for the reference model by constructing
Cox models in the study sample. We refit the reference
model also including a term for the relevant pregnancy
complication to investigate the incremental value of
incorporating this information. Using the observed 10-year
survival and estimated betas [22] we calculated the 10-year
CVD risk for each participant as predicted by each model.
To describe changes in model discrimination with the
addition of the pregnancy complication history, we calcu-
lated the difference in c-index and integrated discrimina-
tory improvement (IDI). To report relevant improvement in
model risk reclassification, we calculated categorical net
reclassification improvement (NRI) separately for cases
and non-cases. To reflect current clinical guidelines on
primary prevention, we used the following three groups to
categorize 10-year CVD risk: \ 5, 5–10, and [ 10%
[23, 24]. Bootstrapping (1000 iterations) was used to esti-
mate 95% confidence intervals (CI) for model compar-
isons. Tests of calibration (GND test) were performed for
all prediction models. Analyses were performed using SAS
9.4 (SAS Institute, Inc., Cary, NC, USA). The publicly-
available macros used for prediction model evaluation
were developed by Cook et al. [25]. Several additional sub-
analyses are described in the Supplement file.
Results
Table 1 presents baseline characteristics of the study
sample by age at clinical assessment as the association
between LBW and CVD differed by age (see below).
Women assessed at age 60 years had a worse CVD risk
profile compared to those assessed at age 50 years, with the
exception that smoking was less prevalent at age 60 years.
During the 10 years following clinical assessment at age
50 years, 132 (1.7%) women died from non-CVD causes
and 15 (0.2%) emigrated; corresponding numbers were 200
(3.7%) and four (0.1%), respectively, for women assessed
at age 60 years. Among women age 50 years at baseline,
257 (3.4%) experienced a CVD event within 10 years
whereas 405 (7.6%) women followed from age 60 years
experienced an event.
Association between predictors at clinical
assessment and 10-year CVD incidence
In the univariate analysis, both history of HDP (HR = 1.90,
95% CI 1.20, 2.99) and LBW offspring (HR = 1.95, 95%
CI 1.38, 2.75) were associated with 10-year CVD in
women age 50. However, there were no similar associa-
tions in women age 60 years for HDP (HR = 1.04, 95% CI
0.68, 1.60, p = 0.05 for interaction by age) or LBW off-
spring (HR = 1.04, 95% CI 0.71, 1.51, p = 0.03 for inter-
action by age). When adjusted for reference model
predictors, LBW was associated with CVD at age 50 years
(Table 2, HR = 1.68, 95% CI 1.19, 2.37) but not at age
60 years (Table 3, HR = 0.94, 95% CI 0.65, 1.38, p = 0.04
for interaction by age). When adjusted for reference model
predictors, history of HDP was not associated with 10-year
CVD in either the age stratified models (Table 2 and
Table S1) or the non-age stratified model (Table S2).
History of HDP was therefore not examined further in the
main analysis.
The value of pregnancy complication history for 10-year cardiovascular disease risk…
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Table 1 Baseline characteristics
of study sample and first CVD
event during 10-year follow-up
by age at clinical assessment
(n = 11110)
Characteristic Age 50a Age 60a
Number of participants 7552 (68.0%)b 5360 (48.2%)b
Systolic blood pressure, mmHg, median (IQR) 125 (115, 140) 136 (122, 150)
Total serum cholesterol, mmol/L, median (IQR) 5.64 (5.00, 6.38)c 5.96 (5.29, 6.70)d
Anti-hypertensive medication 811 (10.7) 1214 (22.7)
Current smoker 1851 (24.5) 1007 (18.8)
Diabetes mellitus 66 (0.9) 138 (2.6)
Body mass index, kg/m2, median (IQR) 24.7 (22.7, 27.6) 25.9 (23.5, 28.9)
Parity
1 2926 (38.7) 1678 (31.3)
2 3394 (44.9) 2646 (49.4%)
3 981 (13.0) 833 (15.5)
C 4 251 (3.3) 203 (3.8)
Ever hypertensive disorder of pregnancy 328 (4.3) 285 (5.3)
Ever low birth weight offspring (\ 2500 g) 624 (8.3) 373 (7.0)
First CVD event during 10 years of follow-up 257 (3.4) 405 (7.6)
Myocardial infarction 101 (1.3) 149 (2.8)
Angina 67 (0.9) 93 (1.7)
Stroke 72 (1.0) 125 (2.3)
TIA 22 (0.3) 46 (0.9)
Presented as n (%) unless otherwise noted
CVD cardiovascular disease, IQR interquartile range, TIA transient ischemic attack
a ± 0.5 years
bA subset of participants attended clinical visits at both age 50 and 60 years
cn = 5666 participants (75.0%) with hypercholesterolemia (C 5.0 mmol/l) and 37 (0.5%) with lipid low-
ering medication at age 50 years
dn = 4488 participants (83.7%) with hypercholesterolemia (C 5.0 mmol/l) and 167 (3%) with lipid low-
ering medication at age 60 years
Table 2 Estimates for 10-year
CVD model predictors among
women assessed at age 50
(n = 7552) by added pregnancy
complication
Reference model ? Low birth weight offspring (\ 2500 g)
Predictor Beta SE Hazard ratio (95% CI) p value
Log total cholesterol 1.19 0.33 3.28 (1.72, 6.24) \ 0.001
Log systolic blood pressure 3.22 0.45 25.1 (10.5, 60.2) \ 0.001
Anti-hypertensive medication 0.51 0.16 1.66 (1.22, 2.26) 0.001
Current smoker 0.83 0.13 2.30 (1.79, 2.96) \ 0.001
Diabetes mellitus 0.99 0.36 2.69 (1.32, 5.51) 0.007
Low birth weight offspring 0.52 0.18 1.68 (1.19, 2.37) 0.003
Reference model ? Hypertensive disorders of pregnancy
Predictor Beta SE Hazard ratio (95% CI) p value
Log total cholesterol 1.19 0.33 3.29 (1.72, 6.27) \ 0.001
Log systolic blood pressure 3.20 0.45 24.4 (10.1, 59.1) \ 0.001
Anti-hypertensive medication 0.51 0.16 1.67 (1.22, 2.29) 0.001
Current smoker 0.85 0.13 2.34 (1.82, 3.01) \ 0.001
Diabetes mellitus 1.02 0.37 2.77 (1.35, 5.67) 0.005
Hypertensive disorders of pregnancy 0.17 0.24 1.19 (0.74, 1.90) 0.48
CI Confidence interval
S. Timpka et al.
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Incremental value of LBW offspring in CVD
prediction when added to the reference model
Table 3 presents the risk reclassification separately for
events and non-events, as well as discrimination statistics
for adding LBW offspring to the reference model in
women age 50 years. A greater proportion of the women
who developed CVD were assigned to a higher risk cate-
gory (categorical NRI for events 0.038; 95% CI 0.003,
0.074) but the risk classification among women without an
event remained constant (categorical NRI for non-events:
- 0.001; 95% CI - 0.006, 0.003). The reference model
had adequate discriminatory performance (c-index: 0.69,
95% CI 0.66, 0.72) but adding information on LBW did not
improve discrimination further. All prediction models were
adequately calibrated as tested by the GND test (p[ 0.05).
Additional results
Supplementary results, including risk reclassification
tables for HDP and for overall analyses (i.e. not stratified
by age) can be found in the Supplement (Table S3 to
Table S8). These analyses supported the results of the main
analysis presented here. In addition, the sensitivity analyses
described in the Supplement, including restricting the
outcome to hard CVD events, investigating 7.5% 10-year
CVD risk as cut-off, or restricting HDP diagnoses to
diagnoses related to preeclampsia, supported the main
results.
Discussion
In this study of parous women, both history of HDP and
having delivered LBW offspring were associated with
increased risk of CVD at age 50 but not 60 years. How-
ever, when added to conventional CVD risk factors,
10-year CVD risk prediction was not meaningfully
improved. To our knowledge, this is the first comprehen-
sive investigation of the incremental value of history of
HDP or LBW offspring for predicting 10-year risk of CVD.
Parikh et al. [26] tested the clinical value of adding a range
of reproductive factors, but not HDP or LBW, to a pre-
diction model that included conventional predictors in a
sample of mostly older middle-aged women. Discrimina-
tion and risk reclassification for non-cases, but not for
cases, were slightly improved.
The crude association between each pregnancy com-
plication and 10-year CVD at age 50 years is consistent
with the two-fold increased risk reported in previous
studies [1–5]. The observed null association between HDP
and CVD in women 60 years of age in this cohort could
potentially be due to less adequate diagnoses at the time of
pregnancy, as these women partly belong to a different
birth cohort, compared to women with a clinical exami-
nation at age 50 years. However, a similar pattern is evi-
dent also for LBW offspring, which, being defined only by
offspring birth weight, might be less sensitive to temporal
changes in definition than a clinical diagnosis of HDP.
Table 3 Risk reclassification
for 10-year CVD prediction in
women age 50 years with low
birth weight offspring added to
the reference model
Women with CVD events during 10-year follow-up
Reference model ? LBW offspring (\ 2500 g)
Reference model 0 to\ 5% 5 to\ 10% C 10% Total
0 to\ 5% 138 (92.6) 11 (7.4) 0 149 (58.0)
5 to\ 10% 5 (7.5) 57 (85.1) 5 (7.5) 67 (26.1)
C 10% 0 1 (2.4) 40 (97.6) 41 (16.0)
Total 143 (55.6) 69 (26.9) 45 (17.5) 257
Women with no CVD events during 10-year follow-up
Reference model ? LBW offspring (\ 2500 g)
Reference model 0 to\ 5% 5 to\ 10% C 10% Total
0 to\ 5% 5828 (98.0) 119 (2.0) 0 5947 (83.2)
5 to\ 10% 128 (12.9) 806 (81.3) 58 (5.9) 992 (13.9)
C 10% 0 38 (18.2) 171 (81.8) 209 (2.9)
Total 5956 (83.3) 963 (13.5) 229 (3.2) 7148
Data presented as n (%). Women censored due to non-events within 10-years of baseline are excluded from
the table (n = 147). Categorical NRI for events = 0.038 (95% CI 0.003, 0.074, p = 0.04). Categorical NRI
for non-events = - 0.001 (95% CI - 0.006, 0.003, p = 0.63). IDI = 0.0014 (95% CI - 0.0002, 0.0032,
p = 0.10). C-index reference model = 0.69 (95% CI 0.66, 0.72). C-index reference model ? LBW = 0.70
(95% CI 0.66, 0.73). C-index difference = 0.01 (95% CI - 0.0003, 0.02)
CI Confidence interval, CVD cardiovascular disease, IDI integrated discriminatory improvement, LBW low
birth weight (\ 2500 g), NRI net reclassification improvement
The value of pregnancy complication history for 10-year cardiovascular disease risk…
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Though the c-statistics for the reference model might
appear modest, it is important to consider that age is a
strong predictor of CVD. Many previous studies of CVD
prediction have reported c-statistics close to 0.8, but
include a wider and continuous age range of participants
than this sample [15, 22, 27–29] However, with age being a
strong risk factor for CVD, an age restricted sample results
in lower discrimination. A relevant comparison is a study
including men approximately age 71 years by Zethelius
et al. [30] which reported a C-statistic of 0.69 for 10-year
risk of CVD death in a model with conventional CVD
predictors.
Strengths and limitations
This study has several strengths that should be noted: a
previously published CVD prediction model was utilized as
reference, few women were censored during the 10-year
intervals, and the baseline data collection was standardized.
Though our sample is not a naı¨ve treatment cohort without
preventive measures during follow-up, it reflects primary
health care settings in which conventional CVD risk factors
are collected and treated if appropriate. More importantly,
only recently has the topic of pregnancy complications
been featured in European CVD prevention guidelines,
appearing in the European Society of Cardiology guideli-
nes for CVD prevention for the first time in 2016 [7]. Thus,
the treatment of the study sample throughout follow-up is
likely to be unbiased in this regard as history of HDP or
LBW offspring were unlikely to directly affect any pre-
ventive health care received. However, there are also some
limitations. We did not have data on high-density
lipoprotein (HDL) or C-reactive protein (CRP) on all par-
ticipants, which prevented us from utilizing several CVD
prediction models as Refs. [27–29, 31] Nevertheless, if
history of HDP and LBW offspring do not provide incre-
mental value to our prediction model without HDL, this
information is not likely to further improve prediction
models with even better performance. All women in the
sample were age 50–60 years, limiting generalizability to
younger women, and we did not have data on current
menopausal status. However, menopause is generally not
considered in clinical CVD prediction models in women.
Strictly speaking, the generalizability is also limited to
women who were living in the geographical area of the
pregnancy registry from young adulthood and attended the
clinical visits in middle age. However, it seems unlikely
that the exclusion of women with incomplete reproductive
history based on relocation (e.g. pursuing higher education)
would influence our results. While many studies on preg-
nancy complications and later CVD have relied on registry-
based data [2, 3, 19], chart review confirmation is more
common in studies of CVD prediction. Here, the pregnancy
exposures and CVD outcomes were ascertained via registry
based ICD code data and not through chart review. For the
purpose of this study, the validation of in-patient registry
based diagnoses of stroke and myocardial infarction
appears to be adequate (positive predictive value generally
[ 80%) [21]. Furthermore, the registry-based prospective
follow-up for events results in\ 4% of participants lost to
follow-up.
Implications for future research
Whereas we did not find meaningful utility of incorporat-
ing history of HDP or LBW offspring in CVD prediction in
this population of middle-aged parous women of Scandi-
navian ethnicity, this topic warrants evaluation in other
populations that also include high-quality data on gesta-
tional age and gestational diabetes mellitus, both of which
have been associated with maternal CVD [1]. In particular,
preterm delivery appears to be associated with CVD
independently of the cardiovascular risk factors included in
CVD risk prediction models [32], and could improve CVD
prediction better than HDP or LBW. As the clinical diag-
noses of HDP are likely to have improved since the
1950–1960s, e.g. due to the clinical implementation of
urine dipsticks to detect proteinuria and through consensus
guidelines, it cannot be excluded that HDP diagnoses set
according to these more strict and defined definitions might
have greater relevance for CVD prediction in women of
younger generations.
This study did not include nulliparous women. Whereas
one study found that nulliparity was associated with
increased risk of CVD in women [33], another study did not
find an association between ever being pregnant and coro-
nary heart disease when adjusting for established CVD risk
factors [26]. Nonetheless, to study the clinical utility of
pregnancy complications in predicting CVD in all women,
future studies should preferably includewomen regardless of
parity. Also, the incremental value of pregnancy complica-
tions in predicting CVDmight differ by race/ethnicity given
the difference in prevalence of pregnancy complications
[34], and the reported interaction between ethnicity/race,
pregnancy complications, and age on risk of CVD [14].
Finally, we note that pregnancy complication history
might be more predictive of 10-year CVD risk before age
50, at which point CVD risk factors such as hypertension
have emerged. Similarly, pregnancy complications at age
20, 30 or 40 years may predict longer-term CVD risk over
several decades. While the current study suggests that
history of HDP or LBW offspring does little to predict
CVD risk in addition to already established CVD risk
factors at age 50 or 60 years, history of pregnancy com-
plications may still be useful to identify young women to
prevent the development of the hypertension, dyslipidemia,
S. Timpka et al.
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overweight and diabetes with which these pregnancy
complications are associated.
Conclusion
In this cohort of women aged 50 and 60 years, information
on prior HDP or LBW offspring did not meaningfully
improve 10-year CVD risk prediction when added to an
established prediction model that already accounted for
conventional CVD risk measured at those ages. This sug-
gests that, for women age 50 and older, pregnancy com-
plication history does not add to CVD risk stratification.
However, at younger ages not tested with this study,
pregnancy complication history is known to predict the
development of conventional CVD risk factors [1, 13, 14],
and may still improve clinical risk prediction before age
50. Therefore, these factors should still be evaluated in
CVD risk prediction models in younger women, as well as
in other populations.
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